Evaluating pain management strategies in sickle cell patients
Cohort Study of Sickle Cell Patients Evaluating Analgesic Strategies and Their Consequences
Assistance Publique - Hôpitaux de Paris · NCT06650059
This study is trying to see how adults with sickle cell disease manage their pain with medications like opioids and cannabis, and to understand how common opioid use disorder is among them.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 600 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Assistance Publique - Hôpitaux de Paris (other) |
| Locations | 3 sites (Créteil and 2 other locations) |
| Trial ID | NCT06650059 on ClinicalTrials.gov |
What this trial studies
This observational study aims to gather comprehensive data on the use of analgesics, including opioids and cannabis, among adults with sickle cell disease. It focuses on understanding the prevalence of opioid use disorder in this population, which preliminary data suggests is alarmingly high. The study will utilize a questionnaire to collect information from patients receiving care at three reference centers in Paris. By analyzing this data, the research seeks to inform better multidisciplinary care strategies for managing pain in sickle cell patients.
Who should consider this trial
Good fit: Ideal candidates for this study are adult patients diagnosed with sickle cell disease who are receiving treatment at designated reference centers.
Not a fit: Patients who are under guardianship or curatorship, or those who are non-literate, may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved pain management strategies and reduced opioid dependency in sickle cell patients.
How similar studies have performed: While there is limited data specifically on this approach, the high prevalence of opioid use disorder in similar patient populations suggests that further investigation is warranted.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patient. * Sickle cell patient benefiting from a consultation or a session in a day hospital in one of the three reference centers (Necker Hospital, Mondor Hospital, Georges Pompidou European Hospital). * Patient informed of the study and not opposed to participating in the research. Exclusion Criteria: * Patient under guardianship or curatorship. * Non-literate patient.
Where this trial is running
Créteil and 2 other locations
- Hôpital Henri Mondor — Créteil, France (RECRUITING)
- Hôpital européen Georges-Pompidou — Paris, France (RECRUITING)
- Hôpital Necker-Enfants Malades — Paris, France (RECRUITING)
Study contacts
- Principal investigator: Laure Joseph, M.D. — Assistance Publique - Hôpitaux de Paris
- Study coordinator: Laure Joseph, M.D.
- Email: laure.joseph@aphp.fr
- Phone: 0033144495591
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Sickle Cell Disease, Sickle cell disease, Intense painful vaso-occlusive crises, Opioid use disorder